Self‐efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression
- 3 January 2013
- journal article
- research article
- Published by Wiley in Psycho-Oncology
- Vol. 22 (9) , 1972-1978
Abstract
Objective: The purpose of this study was to explore the impact of self‐efficacy for coping with cancer (SECC) on physical fatigue and depressive symptoms in melanoma patients, in comparison with objective factors, such as treatment with interferon‐alpha (IFN‐α) and medical and sociodemographic variables. Current literature shows that psychological distress in melanoma patients is generally moderate, that they experience high quality of life, and that symptoms of depression and fatigue have been mostly associated with adjuvant IFN‐α treatmentMethods: A total of 175 melanoma patients, stages Ib–IIIc with and without low‐dose IFN‐α therapy, completed surveys on SECC, depression, and fatigue. Two hierarchical regression analyses were conducted to explore the predictive role of objective factors (first step: tumor stage, time since diagnosis, and current IFN‐α treatment; second step: age and gender) in conjunction with the subjective factor of SECC (third step) on physical fatigue and depression.Results: Regression analysis revealed no significant effect of IFN‐α treatment upon depression. Current IFN‐α treatment was predictive of higher fatigue scores, however. The highest predictive effect by far was obtained for SECC, indicating higher fatigue and depression in patients with lower SECC.Conclusions: The findings suggest that the treatment with IFN‐α is mainly accompanied by physical fatigue in melanoma patients rather than by mood changes. Most notably, the potential influence of increased SECC on reducing both physical fatigue and depression is suggested by the data, indicating the importance of self‐efficacy enhancing interventions in the psycho‐oncological support of melanoma patients. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 42 references indexed in Scilit:
- Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trialThe Lancet Oncology, 2011
- Testing a Theoretical Model of Perceived Self-efficacy for Cancer-Related Fatigue Self-management and Optimal Physical Functional StatusNursing Research, 2009
- Objective and subjective stressors and the psychological adjustment of melanoma survivorsPsycho-Oncology, 2006
- Depressive symptom patterns and their consequences for diagnosis of affective disorders in cancer patientsSupportive Care in Cancer, 2004
- Turning the tide: Benefit finding after cancer surgerySocial Science & Medicine, 2004
- Anxiety and Depressive Symptoms Measured by the Hospital Anxiety and Depression Scale as Predictors of Time to Recurrence in Localized Cutaneous MelanomaActa Oncologica, 2004
- Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant MelanomaJournal of Clinical Oncology, 2004
- Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and MethylphenidateOncology Nursing Forum, 2002
- Group coping skills instruction and supportive group therapy for cancer patients: A comparison of strategies.Journal of Consulting and Clinical Psychology, 1986
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983